Real-World Challenges and Solutions with BTKi in CLL: Therapeutic Insights for Community Practice
Real-World Challenges and Solutions with BTKi in CLL: Therapeutic Insights for Community Practice is organized by PVI, PeerView Institute for Medical Education.
Activity Release Date: March 6, 2023
Activity Expiration Date: March 5, 2024
Activity Description:
First- and second-generation Bruton tyrosine kinase (BTK) inhibitors have transformed the standard of care in many different chronic lymphocytic leukemia (CLL) settings—from treatment-naïve to relapsed disease, as well as in high-risk settings—but are you prepared to fully integrate established and emerging BTKi options into clinical practice, including in the context of community-based care? Find out by viewing this activity, which highlights the clinical decision-making of an academic and a community specialist. Throughout, the panelists will use a series of real-world cases to demonstrate the practicalities of using modern BTKi therapy, provide guidance on the use of next-generation agents, and offer a strong grounding for updated AE management protocols that can ensure safe delivery of care.
Educational Objectives:
Upon completion of this activity, participants should be better able to:
• Summarize evidence from pivotal clinical trials and practice guidelines on BTK inhibitor efficacy, safety, and mechanistic/selectivity differences, including as single-agent approaches or as part of novel combinations
• Recommend personalized BTK inhibitor therapy for patients with treatment-naïve CLL based on prognostic information, the presence of comorbidities, and safety considerations
• Select individualized, sequential BTK inhibitor options for the management of patients with relapsed/refractory CLL or for individuals who develop therapeutic intolerance
• Manage adverse events associated with the use of novel targeted approaches with BTK inhibitors in the CLL setting.